Publicacións en colaboración con investigadores/as de Complejo Hospitalario Torrecárdenas de Almería (10)

2024

  1. Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)

    Trials, Vol. 25, Núm. 1

2023

  1. Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

    European Stroke Journal, Vol. 8, Núm. 1, pp. 380-386

2022

  1. Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

    Neurologia, Vol. 37, Núm. 1, pp. 61-72

2021

  1. Recommendations of the Spanish Society of Neurology for the prevention of stroke. Interventions on lifestyle and air pollution

    Neurologia, Vol. 36, Núm. 5, pp. 377-387

  2. Stroke prevention in patients with arterial hypertension: Recommendations of the Spanish Society of Neurology's Stroke Study Group

    Neurologia, Vol. 36, Núm. 6, pp. 462-471

  3. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology

    Neurologia, Vol. 36, Núm. 4, pp. 305-323

2020

  1. Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (SEN)

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 40, Núm. 3, pp. 272-278

2019

  1. Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort

    Frontiers in Genetics, Vol. 10, Núm. FEB

  2. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem

    Nefrologia

2017

  1. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8